IFM Investors Pty Ltd lifted its position in Johnson & Johnson (NYSE:JNJ) by 52.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,744 shares of the company’s stock after buying an additional 98,316 shares during the quarter. Johnson & Johnson makes up approximately 1.4% of IFM Investors Pty Ltd’s portfolio, making the stock its 8th biggest holding. IFM Investors Pty Ltd’s holdings in Johnson & Johnson were worth $37,099,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Virtus ETF Advisers LLC bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $25,000. Krane Funds Advisors LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $26,000. Financial Advantage Inc. bought a new position in Johnson & Johnson during the third quarter valued at approximately $28,000. Crewe Advisors LLC grew its position in Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the last quarter. Finally, Eii Capital Management Inc. bought a new position in Johnson & Johnson during the third quarter valued at approximately $39,000. 72.25% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have commented on JNJ shares. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Friday, October 11th. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, Credit Suisse Group increased their price target on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $151.64.
Shares of Johnson & Johnson stock traded up $1.57 on Friday, hitting $133.00. The stock had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The stock has a market cap of $343.25 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. The stock’s 50-day simple moving average is $130.83 and its two-hundred day simple moving average is $134.05.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The firm had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter last year, the business earned $2.05 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 8.65 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.